WT1 and breast cancer: In a phase I clinical trial, WT-I vaccination activated WT-1-specific cytotoxic T lymphocytes (CTLs) and resulted in cancer regression with a good safety profile in 2 patients with BC with overexpression of the WT-1 gene and HLA-A*2402-possibility (107).